文献速递妇科

右美托咪定-瑞芬太尼在子宫肌瘤高强度超声消融中的应用:一项随机研究

Application of dexmedetomidine-remifentanil in high-intensity ultrasound ablation of uterine fibroids: a randomised study.
PubMed 文献 · BJOG · 2017-01-01

该随机对照试验将80例子宫肌瘤患者分为右美托咪定组(D组)与咪达唑仑组(M组),比较两种方案在HIFU治疗中的镇痛镇静效果;D组呼吸抑制例数显著更少(P<0.05),HIFU消融中断时间更短,RSS为3或4的患者数更多,患者满意度、恢复评分及术者满意度均更高(P<0.05)。

要点

  • D组呼吸抑制例数显著少于M组(P<0.05)。
  • D组HIFU消融中断时间显著短于M组。
  • D组RSS为3或4的患者数、满意度及恢复评分均显著高于M组(P<0.05)。

核心结论

  • 右美托咪定-瑞芬太尼与咪达唑仑-瑞芬太尼均能满足子宫肌瘤HIFU治疗要求并保证安全。
  • 与咪达唑仑-瑞芬太尼相比,右美托咪定-瑞芬太尼镇静更稳定、HIFU治疗更高效、患者舒适度更高。

研究设计与样本

  • 随机对照试验,在单家医院麻醉科进行。
  • 共80例诊断为子宫肌瘤并计划择期HIFU治疗的患者,随机分为右美托咪定组(D组)和咪达唑仑组(M组)。

主要发现

  • 两组患者均成功完成HIFU手术,术后期间未出现严重并发症。
  • HIFU治疗期间D组呼吸抑制例数显著少于M组(P<0.05)。
  • D组HIFU消融中断时间显著短于M组。
  • HIFU消融强度、不同时间点及唤醒时RSS为3或4的患者数,D组均显著多于M组(P<0.05)。
  • D组患者满意度评分、恢复评分及术者满意度评分均显著高于M组(P<0.05)。

关键数值与推荐

  • D组于HIFU操作前20分钟给予右美托咪定负荷剂量0.8 μg/kg,随后以0.2 μg/kg/小时持续静脉输注至手术结束。
  • M组于操作前缓慢静脉输注咪达唑仑0.03 mg/kg,30分钟后静脉注射0.02 mg/kg,60分钟后再给予0.02 mg/kg,之后每40分钟给予0.02 mg/kg。
  • 两组HIFU操作期间均给予瑞芬太尼,效应部位浓度为1.0 ng/ml。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effects of dexmedetomidine-remifentanil with the traditional analgesia and sedation regimen midazolam-remifentanil during HIFU treatment of uterine fibroids. DESIGN: A randomised controlled trial. SETTING: Department of Anesthesia in a single hospital. POPULATION: Patients with uterine fibroids. METHODS: A total of 80 patients diagnosed with uterine fibroids and scheduled for selective HIFU treatment were randomly divided into the dexmedetomidine group (the D group) and midazolam group (the M group). At 20 minutes before the HIFU procedure, patients in the D group received a loading dose of 0.8 μg/kg dexmedetomidine, followed by a continuous intravenous infusion of 0.2 μg/kg/hour until the end of the operation. Patients in the M group were given a corresponding amount of 0.9% saline. Patients in the M group received a slow intravenous infusion of 0.03 mg/kg midazolam before the procedure, an intravenous injection of 0.02 mg/kg 30 minutes later, another 0.02 mg/kg 60 minutes later, followed by 0.02 mg/kg at 40-minutes intervals. Patients in the D group were given a corresponding amount of 0.9% saline. During the HIFU procedure, patients in both groups were administered remifentanil at an effect site concentration of 1.0 ng/ml. Sedation and analgesia were rated using the Ramsay Sedation Scale (RSS) and Visual Analogue Scale (VAS) before drug administration (T1), after drug administration but before HIFU (T2), at the beginning of HIFU (T3), 15 minutes later (T4), 45 minutes later (T5), 75 minutes later (T6), and at the end of HIFU (T7). Patient satisfaction score and Steward recovery score survey were conducted 30 minutes after surgery. MAIN OUTCOME MEASURES: Different effects of the traditional midazolam-remifentanil regimen and dexmedetomidine-remifentanil. RESULTS: All patients in both groups underwent a successful HIFU procedure without developing serious complications during the postoperative period. However, the D group reported significantly fewer cases of respiratory depression than the M group during HIFU treatment (P < 0.05). The pause during HIFU ablation in the D group was significantly shorter than that in the M group. HIFU ablation intensity, the number of patients with an RSS of 3 or 4 measured at different time points, and the number of patients with an RSS of 3 or 4 measured at arousal were significantly greater in the D than the M group (P < 0.05). Likewise, the D group scored significantly higher in the evaluation of patient satisfaction, recovery score, and surgeon satisfaction (P < 0.05). CONCLUSIONS: Both dexmedetomidine-remifentanil and midazolam-remifentanil met the requirements and ensured the safety of HIFU treatment of uterine fibroids. However, compared with the traditional midazolam-remifentanil regimen, dexmedetomidine-remifentanil was associated with more stable sedation in patients, more efficient HIFU treatment and higher degree of patient comfort. TWEETABLE ABSTRACT: Dexmedetomidine-remifentanil is associated with more stable sedation in patients, more efficient HIFU treatment and higher degree of patient comfort than is midazolam-remifentanil.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Fu X, Huang F, Chen Y, et al. Application of dexmedetomidine-remifentanil in high-intensity ultrasound ablation of uterine fibroids: a randomised study. BJOG. 2017. PMID: 28856857. doi:10.1111/1471-0528.14740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。